John Brendan Doyle net worth and biography

John Doyle Biography and Net Worth

Mr. Doyle joined Cognition Therapeutics as chief financial officer in 2023. He has significant experience raising capital in challenging markets and leading companies through the evolution to commercialization. Most recently he was chief financial officer of 4D Pharma plc, and previously SVP and chief financial officer of Chiasma Inc. During his tenure at Chiasma Inc, the company began reporting commercial sales and ultimately completed a merger with Amryt Pharma. Earlier, he served in finance departments at Verastem Oncology, SimpliVity Corp., PAREXEL, Inc. and Hologic Inc. Mr. Doyle earned a Bachelor of Science in finance from the University of Massachusetts.

What is John Brendan Doyle's net worth?: The estimated net worth of John Brendan Doyle is at least $643.20 thousand as of April 16th, 2026. Doyle owns 627,509 shares of Cognition Therapeutics stock worth more than $643,197 as of September 15th. This net worth estimate does not reflect any other assets that Doyle may own. Learn More about John Brendan Doyle's net worth.
How do I contact John Brendan Doyle?: The corporate mailing address for Doyle and other Cognition Therapeutics executives is , , . Cognition Therapeutics can also be reached via phone at 412-481-2210 and via email at [email protected]. Learn More on John Brendan Doyle's contact information.
Has John Brendan Doyle been buying or selling shares of Cognition Therapeutics?: John Brendan Doyle has not been actively trading shares of Cognition Therapeutics over the course of the past ninety days. Most recently, on Thursday, April 16th, John Brendan Doyle bought 10,000 shares of Cognition Therapeutics stock. The stock was acquired at an average cost of $1.13 per share, with a total value of $11,300.00. Following the completion of the transaction, the chief financial officer now directly owns 627,509 shares of the company's stock, valued at $709,085.17. Learn More on John Brendan Doyle's trading history.
Who are Cognition Therapeutics' active insiders?: Cognition Therapeutics' insider roster includes John Doyle (CFO), and Peggy Wallace (Director). Learn More on Cognition Therapeutics' active insiders.
Are insiders buying or selling shares of Cognition Therapeutics?: During the last year, Cognition Therapeutics insiders bought shares 2 times. They purchased a total of 19,175 shares worth more than $21,392.50. The most recent insider tranaction occured on April, 16th when CFO John Brendan Doyle bought 10,000 shares worth more than $11,300.00. Insiders at Cognition Therapeutics own 11.1% of the company. Learn More about insider trades at Cognition Therapeutics.
Information on this page was last updated on 4/16/2026.

John Brendan Doyle Insider Trading History at Cognition Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
4/16/2026	Buy	10,000	$1.13	$11,300.00	627,509

John Brendan Doyle Buying and Selling Activity at Cognition Therapeutics

Cognition Therapeutics Company Overview

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Today's Range

Now: $1.04

$0.98

$1.04

50 Day Range

MA: $1.00

$0.89

$1.13

2 Week Range

Now: $1.04

$0.55

$2.05

Volume

353,467 shs

Average Volume

1,085,300 shs

Market Capitalization

$98.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.79